Molecular dynamics exploration of Lupenone: therapeutic implications for glioblastoma multiforme and alzheimer's

Hailah M Almohaimeed1, Amany I Almars2, Waleed Al Abdulmonem3

  • 1Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman University, P.O. Box 84428, 11671, Riyadh, Saudi Arabia.

Metabolic Brain Disease
|December 22, 2023
PubMed

Insights

Lupenone shows promise for treating glioblastoma and Alzheimer's disease by targeting key proteins. Further research is recommended to validate its therapeutic potential in clinical settings.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Computational Biology

Background:

  • Glioblastoma and Alzheimer's disease present significant therapeutic challenges due to complex molecular pathways.
  • Novel therapeutic strategies are crucial for addressing these neuro-oncological and neurodegenerative disorders.

Purpose of the Study:

  • To investigate the therapeutic potential of Lupenone, a phytoconstituent, against glioblastoma and Alzheimer's amyloid beta pathology.
  • To assess Lupenone's interaction with key protein targets (5H08 and 2ZHV) using computational methods.

Main Methods:

  • Employed an integrative approach combining proteomics and computer-aided drug design.
  • Performed molecular docking and molecular dynamics simulations to analyze Lupenone-protein interactions.
  • Investigated the potential enhancement of Lupenone's efficacy using Proteolysis Targeting Chimeras (PROTACs).

Main Results:

  • Lupenone exhibited strong binding affinities to 5H08 (-9.54 kcal/mol) and 2ZHV (-10.59 kcal/mol).
  • These interactions suggest Lupenone's potential to mitigate glioblastoma and modulate Alzheimer's amyloid beta pathology.
  • PROTACs further enhanced the therapeutic prospects of Lupenone.

Conclusions:

  • Lupenone demonstrates significant therapeutic potential for glioblastoma and Alzheimer's disease based on in-silico findings.
  • The study provides a strong foundation for considering Lupenone in future neurodegenerative and neuro-oncological research.
  • Empirical validation in in-vivo settings is warranted to explore Lupenone's full therapeutic capacity.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...